MKI67 and neoplasm: Factors we routinely consider in advising women with pT1-3N0disease regarding the need for PMRT include age/menopausal status,comorbidities/life expectancy, tumor size, margin status, LVSI, molecularsubtype, tumor grade/Ki67, anatomic tumor location, receipt of systemic therapy,toxicity risks (e.g. extent of lymph node [LN] surgery, reconstruction, andlaterality with respect to cardiac risk), and patient preference.